Education
About Us
Working with TipRanks
Follow Us
Adaptive Biotechnologies Corp (ADPT)
NASDAQ:ADPT
Earnings Data
Report Date
Jul 30, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.24Last Year’s EPS
-0.31Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 01, 2025
|% Change Since: 37.77%
|Next Earnings Date:Jul 30, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted robust growth in MRD revenue, improved gross margins, and strategic advancements in payer contracting, along with a significant reduction in cash burn. However, there was a slight decline in Immune Medicine revenue due to expected reductions in Genentech amortization.Company Guidance
During the earnings call for Adaptive Biotechnologies, the company provided updated guidance reflecting improved financial performance and strategic initiatives. They reported a 34% increase in MRD revenue year-over-year, driven by growth in clinical volumes, ASPs, and pharma sequencing. The company raised its full-year MRD revenue guidance to $180-$190 million, with an expectation of approximately 30% clonoSEQ test volume growth. Sequencing gross margin improved by 17 percentage points to 62%, and operating expenses decreased by 9%, resulting in a cash burn reduction of 38% compared to the previous year. Adaptive's cash position was reported at $233 million, providing confidence in achieving strategic objectives without raising additional capital. The company aims to achieve an average ASP of $1,300 per test for fiscal year 2025, with expectations to be adjusted EBITDA positive in the second half of the year. The management highlighted continued progress in their immune medicine business and upcoming launches and integrations to further drive growth.Strong MRD Revenue Growth
MRD revenue increased by 34% to $43.7 million, with clinical and pharma contributions of 65% and 35%, respectively. ClonoSEQ clinical revenue grew by 55% versus the prior year.
Sequencing Gross Margin Improvement
Sequencing gross margin improved by 17 percentage points year-over-year to 62%.
Reduction in Operating Expenses
Operating expenses decreased by 9%, highlighting disciplined cost management.
Cash Burn Reduction
Cash burn for the quarter was $23 million, a 38% improvement compared to the same period last year.
Record ClonoSEQ Test Volumes
Tests delivered reached a new record high of over 23,000 in the quarter, representing a 36% increase versus the prior year.
Successful Payer Contracting
Closed six key agreements with major national payers, including Aetna, Humana, and Anthem, aiming for an average ASP of $1,300 per test for fiscal year 2025.
ADPT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ADPT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 01, 2025 | $7.36 | $9.84 | +33.70% |
Feb 11, 2025 | $7.80 | $7.55 | -3.21% |
Nov 07, 2024 | $5.63 | $5.82 | +3.37% |
Aug 01, 2024 | $4.45 | $4.30 | -3.37% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Adaptive Biotechnologies Corp (ADPT) report earnings?
Adaptive Biotechnologies Corp (ADPT) is schdueled to report earning on Jul 30, 2025, TBA Not Confirmed.
What is Adaptive Biotechnologies Corp (ADPT) earnings time?
Adaptive Biotechnologies Corp (ADPT) earnings time is at Jul 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ADPT EPS forecast?
ADPT EPS forecast for the fiscal quarter 2025 (Q2) is -0.24.